Appropriate use of bendamustine in first-line therapy of chronic lymphocytic leukemia. Recommendations from SIE, SIES, GITMO Group

Antonio Cuneo, Monia Marchetti, Giovanni Barosi, Atto Billio, Maura Brugiatelli, Stefania Ciolli, Luca Laurenti, Francesca Romana Mauro, Stefano Molica, Marco Montillo, Pierluigi Zinzani, Sante Tura

Research output: Contribution to journalArticlepeer-review

Abstract

By using the GRADE system we produced the following recommendations for the use of bendamustine in the first-line treatment of CLL: (1) bendamustine with rituximab is recommended in elderly fit patients potentially eligible to FCR; (2) Bendamustine alone is recommended in patients who are candidate to chlorambucil alone; (3) Rituximab-bendamustine is recommended in patients not eligible to FCR, but suitable to receive rituximab. Consensus-based recommendations addressed evidence-orphan issues concerning the use of bendamustine in genetically-defined high-risk patients and the appropriate dose of bendamustine as single agent or in association with rituximab.

Original languageEnglish
Pages (from-to)1269-1277
Number of pages9
JournalLeukemia Research
Volume38
Issue number11
DOIs
Publication statusPublished - Nov 1 2014

Keywords

  • Bendamustine
  • Chronic lymphocytic leukemia
  • First line treatment
  • Guidelines

ASJC Scopus subject areas

  • Cancer Research
  • Hematology
  • Oncology
  • Medicine(all)

Fingerprint Dive into the research topics of 'Appropriate use of bendamustine in first-line therapy of chronic lymphocytic leukemia. Recommendations from SIE, SIES, GITMO Group'. Together they form a unique fingerprint.

Cite this